Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Boston Scientific Corp (NYSE: BSX) closed the day trading at $92.53 down -1.40% from the previous closing price of $93.84. In other words, the price has decreased by -$1.40 from its previous closing price. On the day, 12.67 million shares were traded. BSX stock price reached its highest trading level at $94.84 during the session, while it also had its lowest trading level at $92.26.
Ratios:
For a better understanding of BSX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 99.91 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.87. For the most recent quarter (mrq), Quick Ratio is recorded 0.96 and its Current Ratio is at 1.51. In the meantime, Its Debt-to-Equity ratio is 0.51 whereas as Long-Term Debt/Eq ratio is at 0.49.
On September 08, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $125.
On June 16, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $118.Leerink Partners initiated its Outperform rating on June 16, 2025, with a $118 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Butcher Arthur C sold 17,313 shares for $101.55 per share. The transaction valued at 1,758,189 led to the insider holds 23,600 shares of the business.
ARTHUR C BUTCHER bought 17,313 shares of BSX for $1,758,188 on Dec 01 ’25. On Nov 06 ’25, another insider, Zane Ellen M, who serves as the Director of the company, sold 12,891 shares for $98.28 each. As a result, the insider received 1,266,978 and left with 24,134 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BSX now has a Market Capitalization of 137170354176 and an Enterprise Value of 150118367232. As of this moment, Boston’s Price-to-Earnings (P/E) ratio for their current fiscal year is 49.49, and their Forward P/E ratio for the next fiscal year is 26.66. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.65. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.09 while its Price-to-Book (P/B) ratio in mrq is 5.86. Its current Enterprise Value per Revenue stands at 7.758 whereas that against EBITDA is 29.603.
Stock Price History:
The Beta on a monthly basis for BSX is 0.67, which has changed by 0.03621912 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, BSX has reached a high of $109.50, while it has fallen to a 52-week low of $85.98. The 50-Day Moving Average of the stock is -6.57%, while the 200-Day Moving Average is calculated to be -8.68%.
Shares Statistics:
Over the past 3-months, BSX traded about 9.74M shares per day on average, while over the past 10 days, BSX traded about 9039030 shares per day. A total of 1.48B shares are outstanding, with a floating share count of 1.48B. Insiders hold about 0.39% of the company’s shares, while institutions hold 93.40% stake in the company. Shares short for BSX as of 1763078400 were 21076004 with a Short Ratio of 2.16, compared to 1760486400 on 19634328. Therefore, it implies a Short% of Shares Outstanding of 21076004 and a Short% of Float of 1.4199998999999999.
Earnings Estimates
Boston Scientific Corp (BSX) is currently under the scrutiny of 27.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.79, with high estimates of $0.85 and low estimates of $0.75.
Analysts are recommending an EPS of between $3.07 and $2.98 for the fiscal current year, implying an average EPS of $3.03. EPS for the following year is $3.47, with 32.0 analysts recommending between $3.62 and $3.35.
Revenue Estimates
26 analysts predict $5.28B in revenue for. The current quarter. It ranges from a high estimate of $5.33B to a low estimate of $5.25B. As of. The current estimate, Boston Scientific Corp’s year-ago sales were $4.56BFor the next quarter, 26 analysts are estimating revenue of $5.2B. There is a high estimate of $5.31B for the next quarter, whereas the lowest estimate is $5.12B.
A total of 31 analysts have provided revenue estimates for BSX’s current fiscal year. The highest revenue estimate was $20.23B, while the lowest revenue estimate was $20.03B, resulting in an average revenue estimate of $20.08B. In the same quarter a year ago, actual revenue was $16.75BBased on 32 analysts’ estimates, the company’s revenue will be $22.37B in the next fiscal year. The high estimate is $23.86B and the low estimate is $22.01B.
